Resonance Health Limited operates in the Electromedical equipment sector. Resonance Health Limited is a healthcare company engaged in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and controlled environment. The Company specializes in the provision of image analysis services and the development of quantitative magnetic resonance imaging (MRI) diagnostic technology, with a subspecialty in the liver. The Company's core product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver. The Company has three segments: FerriScan, Research and Development and Corporate. The Company operates in Australia and the United States. During the fiscal year ended June 30, 2010 (fiscal 2010), it launched FerriScan Rapide, which provided a 60% reduction in the FerriScan MRI scan time. During fiscal 2010, it launched cardiac iron assessment test called Cardiac T2 in the United Kingdom and Australia. In our complete report available for purchase the company is compared to: Uscom Ltd, OMI Holdings Limited and Multistack International Limited.